Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 1/20 | 0.31 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LYN | P07948 | 1/20 | 0.30 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4482238 | 0.96 | LYN (0.32) | LYNHCRTR1HCRTR2 | |
| SCHEMBL4745295 | 0.93 | KDM4E (0.32) | BPTFCECR2BRD9KDM4ELYN | |
| SCHEMBL4490928 | 0.90 | KDM4E (0.32) | BPTFCECR2BRD9KDM4ELYN | |
| SCHEMBL4489726 | 0.89 | KDM4E (0.30) | KDM4E | |
| SCHEMBL4741763 | 0.88 | KDM4E (0.35) | BPTFCECR2BRD9KDM4ELYN | |
| SCHEMBL3993899 | 0.87 | TP53 (0.33) | — | |
| SCHEMBL4485590 | 0.87 | TP53 (0.33) | — | |
| SCHEMBL4913222 | 0.87 | PDPK1 (0.32) | — | |
| SCHEMBL4478591 | 0.87 | HDAC1 (0.33) | — | |
| SCHEMBL4487540 | 0.87 | FPR1 (0.33) | LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186907-A1 | Pyrazinones As Cellular Proliferation Inhibitors | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2009-07-23 | — | — | US | claimed |
| US-20090186907-A1 | Pyrazinones As Cellular Proliferation Inhibitors | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186907-A1 | Pyrazinones As Cellular Proliferation Inhibitors | MKI67, NR0B1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | BPTF 1324/4885CECR2 257/4885BRD9 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.